Endo International (ENDP) – PRNewswire
-
Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting
-
ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS
-
C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation
-
Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe
-
Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension
-
Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation
-
New Drug Filing for Cenobamate Accepted for Review in Canada and Israel
-
ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS
-
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada
-
Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor
-
Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder
-
Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain
-
National Survey of Over 1,500 Men Shows More Than Half Were Unsure of How to Improve Their Mental and Sexual Health; New Partnership Aims to Change That Through Education and Free Virtual Consultation
-
Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600
-
ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS
-
Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting
-
Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar
-
Tennessee Court of Appeals Orders Recusal of Trial Court Judge and Vacates Default Judgment on Liability Against Endo
-
Endo to Announce First-Quarter 2022 Financial Results
-
Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials
-
Endo Launches New Living Our Values Program to Recognize Outstanding Team Members
-
Butt First: Endo Launches First Direct-to-Consumer Campaign for Qwo® (collagenase clostridium histolyticum-aaes) With 200+ Patient Events
-
ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS
-
Endo Comments on Default Judgment on Liability in Tennessee State Court
-
Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles
-
Endo to Announce Fourth Quarter and Full-Year 2021 Financial Results
-
Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims
-
Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism
-
Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development
-
Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients: Watching Education Unfold
-
Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution
-
Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference
-
Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims
-
Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada
-
Endo Announces Favorable Final Ruling in California State Court Opioid Trial
-
Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting
-
Settlement Administrator Angeion Group Announces Proposed Class Action Settlement In Endo Securities Litigation
-
Endo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection
-
Endo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Production of Critical Medicines
-
Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care
-
Endo Reports Third-Quarter 2021 Financial Results And Raises 2021 Financial Guidance
-
California State Court Issues Tentative Ruling in Endo's Favor Following Opioid Trial
-
Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease
-
Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting
-
Endo to Announce Third Quarter 2021 Financial Results
-
Endo Presents New Investigational Collagenase Clostridium Histolyticum (CCH) Survey Data at American Society for Surgery of the Hand (ASSH) Annual Meeting
-
Endo Reaches Agreement in Principle to Settle Louisiana Governmental Opioid Cases and Claims
-
Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States
-
Endo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation
-
Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation
Back to ENDP Stock Lookup
